# TH103 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/th103

> The FDA approved TH103, sponsored by Kalaris Therapeutics, Inc. (KLRS), on January 5, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is TH103 FDA approved?

Yes. The FDA approved TH103, sponsored by Kalaris Therapeutics, Inc. (KLRS), on January 5, 2023. Press release filed with the SEC (EX-99): "On January 5, 2023, the FDA approved Floridas plan for Canadian importation." [Calendar and source filings](https://sec-api.dev/pdufa/th103)

Source: Press release filed with the SEC (EX-99), accession 0001193125-25-056725, https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex992.htm (retrieved 2026-11-12). Last confirmed 2025-03-18. Cite: https://sec-api.dev/pdufa/th103#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | TH103 |
| Codes | TH103 |
| Sponsor | Kalaris Therapeutics, Inc. (KLRS) https://sec-api.dev/companies/klrs/catalysts |
| Indications | [neovascular age-related macular degeneration](https://sec-api.dev/indications/neovascular-age-related-macular-degeneration), neovascular and exudative diseases of the retina |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### January 5, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-18, last confirmed 2025-03-18.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-056725): "On January 5, 2023, the FDA approved Floridas plan for Canadian importation." https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-056725): "On January 5, 2023, the FDA approved Floridas plan for Canadian product importation." https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex993.htm

### Jun 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-05-14, last confirmed 2026-05-12.
- SEC Form 10-Q (accession 0001193125-26-219328): "CDMO, CRO and other third-party preclinical studies, clinical trials and consulting costs increased by $1.4 million as we initiated our Phase 1a clinical trial in TH103 in June 2024 and our Phase 1b/2 clinical trial in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312526219328/klrs-20260331.htm
- SEC Form 10-K (accession 0001193125-26-110659): "CDMO, CRO and other third-party preclinical studies, clinical trials and consulting costs increased by $14.8 million as we initiated our Phase 1a clinical trial in TH103 in June 2024 and our Phase 1b/2 clinical trial in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312526110659/klrs-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-277464): "CDMO, CRO and other third-party preclinical studies, clinical trials and consulting costs increased by $12.1 million as we initiated our Phase 1a clinical trial in TH103 in June 2024 and our Phase 1b/2 clinical trial in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312525277464/klrs-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-107979): "CDMO, CRO and other third-party preclinical studies, clinical trials and consulting costs increased by $4.6 million as we initiated our Phase 1 clinical trial of TH103 in June 2024." https://www.sec.gov/Archives/edgar/data/1754068/000095017025107979/klrs-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-107979): "CDMO, CRO and other third-party preclinical studies, clinical trials and consulting costs increased by $7.9 million as we initiated our Phase 1 clinical trial in TH103 in June 2024." https://www.sec.gov/Archives/edgar/data/1754068/000095017025107979/klrs-20250630.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-119408): "The increase quarter-over-quarter was primarily attributable to an increase in costs related to the outsourcing of manufacturing and clinical-related costs as Kalaris initiated its Phase 1 clinical trial in June 2024." https://www.sec.gov/Archives/edgar/data/1754068/000119312525119408/d916904dex991.htm

### Aug 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-03-18, last confirmed 2025-11-12.
- SEC Form 10-Q (accession 0001193125-25-277464): "We dosed the first patient in our Phase 1a clinical trial of TH103 in August 2024." https://www.sec.gov/Archives/edgar/data/1754068/000119312525277464/klrs-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-056725): "We dosed the first patient in our Phase 1 clinical trial of TH103 in August 2024." https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex992.htm
- SEC Form 10-Q (accession 0000950170-25-107979): "We dosed the first patient in our Phase 1 clinical trial of TH103 in August 2024." https://www.sec.gov/Archives/edgar/data/1754068/000095017025107979/klrs-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-071339): "We dosed the first patient in our Phase 1 clinical trial of TH103 in August 2024." https://www.sec.gov/Archives/edgar/data/1754068/000095017025071339/klrs-20250331.htm

### December 31, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2025-03-18, last confirmed 2025-03-18.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-056725): "CRO expenses increased by $2.9 million during the year ended December 31, 2024 as Kalaris initiated its Phase 1 clinical trial in June 2024." https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex994.htm

### Q3 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2025-03-18, last confirmed 2025-03-18.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-056725): "Kalaris expects to report initial data from Part 1 of its ongoing Phase 1 clinical trial of TH103 in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-056725): "However, we are reviewing the original design of the trial and anticipate modifying the design to help accelerate the development of TH103.We expect to report initial data from Part 1 of the Phase 1 clinical trial in the second half of 2025, with additional follow-up data expected in 2026." https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex993.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-056725): "Age-related Macular Degeneration (nAMD), a leading cause of blindness in the United States and Europe that affected an estimated 1.6 million adults in the United States in 2023, and Kalaris expects to report initial clinical data from Part 1 of the Phase 1 clinical trial in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex994.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-056725): "Currently enrolling nAMD patients in a Phase 1 trial, with initial data from Part 1 of the trial expected in the second half of 2025" https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-056725): "We expect to report initial data from Part 1 of the Phase 1 clinical trial in the second half of 2025 with additional follow up data expected in 2026." https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex993.htm

### Q4 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 1. Indication: neovascular Age-related Macular Degeneration.
- First seen 2025-03-18, last confirmed 2025-08-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-179464): "Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025" https://www.sec.gov/Archives/edgar/data/1754068/000119312525179464/d913327dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-119408): "Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025" https://www.sec.gov/Archives/edgar/data/1754068/000119312525119408/d916904dex991.htm
- SEC Form 10-Q (accession 0000950170-25-107979): "We are enrolling an open label Phase 1 clinical trial of TH103 in patients with neovascular Age-related Macular Degeneration ("nAMD"), a leading cause of blindness in the United States and Europe that affected an estimated 1.6 million adults in the United States in 2023, and we expect to report initial clinical data from Part 1 of the Phase 1 clinical trial in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1754068/000095017025107979/klrs-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-071339): "We are enrolling an open label Phase 1 clinical trial of TH103 in patients with neovascular Age-related Macular Degeneration ("nAMD"), a leading cause of blindness in the United States and Europe that affected an estimated 1.6 million adults in the United States in 2023, and we expect to report initial clinical data from Part 1 of the Phase 1 clinical trial in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1754068/000095017025071339/klrs-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-179464): "Initial clinical data is expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312525179464/d913327dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-119408): "Initial clinical data is expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312525119408/d916904dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-056725): "Enrollment in Part 1 of the trial began in August 2024, with initial data expected in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-179464): "We look forward to reporting initial clinical data later this year which will provide an initial read of safety and efficacy data of TH103 at multiple dose levels and help inform the next stage of our clinical development program." https://www.sec.gov/Archives/edgar/data/1754068/000119312525179464/d913327dex991.htm

### December 17, 2025: interim data readout

- Status: completed, positive. Date confidence: exact. Stage: 1. Indication: neovascular Age-related Macular Degeneration.
- First seen 2025-11-12, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-322950): "Therapeutics, Inc. (NASDAQ: KLRS), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced positive initial data from its Phase 1a single ascending dose (SAD) trial of TH103, a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor, in treatment-na&iuml;ve patients with neovascular age-related macular degeneration (nAMD)." https://www.sec.gov/Archives/edgar/data/1754068/000119312525322950/d25416dex991.htm
- SEC Form 10-Q (accession 0001193125-26-455378): "In December 2025, we announced positive initial data from our Phase 1a SAD trial of TH103, and in July 2026, we announced positive additional data from our Phase 1a SAD trial of TH103 in nAMD from expanded nAMD cohorts, which built on the positive initial data that we announced in December 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312526455378/klrs-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-344532): "In December 2025, we announced positive initial data from our Phase 1a SAD trial of TH103, and in July 2026, we announced positive additional data from our Phase 1a SAD trial of TH103 in nAMD from expanded nAMD cohorts, which built on the positive initial data that we announced in December 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312526344532/klrs-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-219328): "We announced positive initial data from our Phase 1a SAD trial of TH103 in December 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312526219328/klrs-20260331.htm
- SEC Form 10-Q (accession 0001193125-26-219328): "In December 2025, we announced positive initial data from our Phase 1a SAD trial of TH103." https://www.sec.gov/Archives/edgar/data/1754068/000119312526219328/klrs-20260331.htm
- SEC Form 10-K (accession 0001193125-26-110659): "We announced positive initial data from our Phase 1a SAD trial of TH103 in December 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312526110659/klrs-20251231.htm
- SEC Form 10-K (accession 0001193125-26-110659): "In December 2025, we announced positive initial data from our Phase 1a SAD trial of TH103." https://www.sec.gov/Archives/edgar/data/1754068/000119312526110659/klrs-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-109437): "Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025;" https://www.sec.gov/Archives/edgar/data/1754068/000119312526109437/d124100dex991.htm
- SEC Form 10-Q (accession 0001193125-25-277464): "We are enrolling an open label Phase 1a single ascending dose clinical trial of TH103 in patients with neovascular Age-related Macular Degeneration ("nAMD"), a leading cause of blindness in the United States and Europe that affected an estimated 1.6 million adults in the United States in 2023, and we expect to report initial clinical data, including safety, preliminary efficacy (e.g., visual acuity and lesion morphology), and pharmacokinetics, from the Phase 1a clinical trial by year end 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312525277464/klrs-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276060): "Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reported by year end 2025" https://www.sec.gov/Archives/edgar/data/1754068/000119312525276060/d70447dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276060): "Initial clinical data from the Phase 1a clinical trial expected by year end 2025." https://www.sec.gov/Archives/edgar/data/1754068/000119312525276060/d70447dex991.htm

### 2H 2026: interim data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-11-12, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276060): "Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose selection for potential Phase 3 development program; initial clinical data expected in 2H 2026" https://www.sec.gov/Archives/edgar/data/1754068/000119312525276060/d70447dex991.htm
- SEC Form 10-Q (accession 0001193125-25-277464): "The Phase 1b/2 clinical trial replaces a smaller Part 2 design originally planned to follow the ongoing Phase 1a clinical trial, and we expect to report initial clinical data from the Phase 1b/2 clinical trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1754068/000119312525277464/klrs-20250930.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-03-18, last confirmed 2025-03-18.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-056725): "The combined companys cash and cash equivalents of approximately $100 million as of the closing date is expected to be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2026. We are delighted to close this transaction, which we expect will provide us with the financial resources to continue development of TH103 beyond the initiation of our planned Phase 2 clinical trial, said Andrew Oxtoby, CEO of Kalaris Therapeutics." https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-056725): "Assuming successful completion of the ongoing Phase 1 clinical trial of TH103, and subject to the favorable results from such trial and discussions with regulators, we also plan to initiate a Phase 2 clinical trial of TH103 for nAMD in 2026." https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex993.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-056725): "Assuming successful completion of the ongoing Phase 1 clinical trial of TH103, and subject to the results of such trial and discussions with regulators, we plan to initiate a Phase 2 clinical trial in 2026 to further evaluate the safety and efficacy of TH103 for nAMD, which subject to favorable results and discussions with regulators, could be followed by a registrational Phase 3 clinical trial of TH103." https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex993.htm

### 1H 2027: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1/2.
- First seen 2026-07-17, last confirmed 2026-07-17.
- SEC Form 8-K (accession 0001193125-26-306737): "Study results will inform dose selection for potential future Phase 3 trials of TH103, and the Company remains on-track to share initial data from the Phase 1b/2 study in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1754068/000119312526306737/d125006d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-306737): "Study results will inform dose selection for potential future Phase 3 trials of TH103, and Kalaris remains on track to share initial data from the Phase 1b/2 study in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1754068/000119312526306737/d125006dex991.htm

### late 2027: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-03-17, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-109437): "Intend to initiate Phase 3 clinical trials by year-end 2027" https://www.sec.gov/Archives/edgar/data/1754068/000119312526109437/d124100dex991.htm
- SEC Form 10-Q (accession 0001193125-26-455378): "We now intend to initiate Phase 3 clinical trials of TH103 for nAMD in 2028, subject to discussions with regulators and the generation of sufficient data in the ongoing Phase 1b/2 trial to support further development and selection of a Phase 3 dose." https://www.sec.gov/Archives/edgar/data/1754068/000119312526455378/klrs-20260930.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/th103.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TH103 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/th103

```bibtex
@misc{secapidev_pdufa_th103_20261116,
  title        = {TH103 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/th103}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_th103_20261116","title":"TH103 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/th103","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
